4Mustafa Kemal C,Tuba D, Celal A, et al. Four-year study of entecavir efficacy and safety in nucleos (t)ide-naive HBeAg positive chronic hepatitis B patients[J]. Acta Clinica Croatica,2014,53(1) :31-36.
5Yang SC, Lee CM, Hu TH, et al. Virological response to entecavir re- duces the risk of liver disease progression in nucleos (t) ide analogue- experienced HBV-infected patients with prior resistant mutants [ J ]. Journal of Antimicrobial Chemotherapy ,2013,68 ( 9 ) :2154-2163.
6Ahn J, Lee HM, Lim JK, et al. Entecavir safety and effectiveness in a national cohort of treatment-naYve chronic hepatitis B patients in the US-the ENUMERATE study [ J 1. Alimentary Pharmacology & Thera- peutics,2015,43 ( 1 ) : 134-144.
7Tsai MC, Chen CH, Hung CH, et al. A comparison of efficacy and safe- ty of 2-year telbivudine and entecavir treatment in patients with chron- ic hepatitis B:a match-control study [ J ]. Clinical Microbiology and In- fection ,2014,20 ( 2 ) :90-100.
8Wiens A, Lenzi L, Venson R, et al. Comparative Efficacy of Oral Nu- cleoside or Nucleotide Analog Monotherapy Used in Chronic HepatitisB : A Mixed-Treatment Comparison Meta-analysis [ J ]. Phannacothera- py : The Journal of Human Pharmacology and Drug Therapy, 2013,33 (2) :144-151.
9Toy M, Hutton DW, So SK, et al. Cost-Effectiveness and Cost Thresh- olds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China[ J]. Plos One,2015,10( 11 ) :526-535.
10Wiens A, Lenzi L, Venson R, et al. Economic evaluation of treatments for chronic hepatitis B [ J]. The Brazilian Journal of Infectious Disea- ses,2013,17(4) :418-426.
